中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
9期
122-123
,共2页
蛋白磷酸酶2A癌性抑制因子%慢性粒细胞白血病%免疫组化
蛋白燐痠酶2A癌性抑製因子%慢性粒細胞白血病%免疫組化
단백린산매2A암성억제인자%만성립세포백혈병%면역조화
CIP2A%CML%Immunohistochemistry
目的:探讨蛋白磷酸酶2A癌性抑制因子在慢性粒细胞白血病各期中的表达及意义.方法:采用免疫化学SP法测定CIP2A在对照组及CML各期中的表达.结果:CIP2A在CML-AP/BP组的表达显著高于对照组和CML-CP组(P<0.05),CML-CP组和对照组比较差异无统计学意义(P>0.05);CIP2A在CML-AP/BP未缓解组明显高于缓解组(P<0.05).结论:CIP2A在CML-AP/BP骨髓单个核细胞中高表达且与CML发生急变及预后相关.
目的:探討蛋白燐痠酶2A癌性抑製因子在慢性粒細胞白血病各期中的錶達及意義.方法:採用免疫化學SP法測定CIP2A在對照組及CML各期中的錶達.結果:CIP2A在CML-AP/BP組的錶達顯著高于對照組和CML-CP組(P<0.05),CML-CP組和對照組比較差異無統計學意義(P>0.05);CIP2A在CML-AP/BP未緩解組明顯高于緩解組(P<0.05).結論:CIP2A在CML-AP/BP骨髓單箇覈細胞中高錶達且與CML髮生急變及預後相關.
목적:탐토단백린산매2A암성억제인자재만성립세포백혈병각기중적표체급의의.방법:채용면역화학SP법측정CIP2A재대조조급CML각기중적표체.결과:CIP2A재CML-AP/BP조적표체현저고우대조조화CML-CP조(P<0.05),CML-CP조화대조조비교차이무통계학의의(P>0.05);CIP2A재CML-AP/BP미완해조명현고우완해조(P<0.05).결론:CIP2A재CML-AP/BP골수단개핵세포중고표체차여CML발생급변급예후상관.
@@@@Objective:To investigate the expression and significance of cancerous inhibitor of protein phosphatase 2A(CIP2A)in control group and in different phases of CML.Method:The immunohistochemical SP staining was used to detect expression of CIP2A in control group and in different phases of CML.Result:Expression of CIP2A in CML-AP/BP group was significantly higher than that in control group and that in CML-CP group(P<0.05), expression of CIP2A in control group and CML-CP group had no significant difference(P>0.05).CIP2A in no remission group was significantly higher than that in complete remission group(P<0.05).Conclusion:Overexpression of CIP2A in CML bone marrow mononuclear cells plays an important role in CML blast crisis and prognosis.
